OCA
HRMY icon

Octagon Capital Advisors’s Harmony Biosciences HRMY Stock Holding History

Octagon Capital Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-243,500
Closed -$10.8M – 40
2022
Q3 		$10.8M Buy
+243,500
New +$11.9M 1.86% 12

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Octagon Capital Advisors's HRMY Position: Q4 2022 in Review

Octagon Capital Advisors sold out of Harmony Biosciences (HRMY) in Q4 2022, closing a stake of 243,500 shares — an estimated $10.8M sold.

Octagon Capital Advisors first reported a position in HRMY in Q3 2022 and held it in 1 quarter. The position peaked at $10.8M in Q3 2022. 242 funds tracked by Wall St. Rank hold HRMY as of Q4 2022.

  • Octagon Capital Advisors reported no remaining Harmony Biosciences position as of Q4 2022 after selling out during the quarter.
  • Octagon Capital Advisors sold 243,500 Harmony Biosciences shares in Q4 2022, an estimated $10.8M.
  • Octagon Capital Advisors first reported a position in Harmony Biosciences in Q3 2022 and held it in 1 quarter.
  • Octagon Capital Advisors's Harmony Biosciences position peaked at $10.8M in Q3 2022.
  • 242 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2022.

Based on Octagon Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.